Quantisnow Logo
Dashboard

Catheter Precision Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$VTAK
Medical/Dental Instruments
Health Care
Get the next $VTAK alert in real time by email
vtak20250311_8k.htm
false 0001716621 0001716621 2025-03-12 2025-03-12
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 12, 2025
 
 
Catheter Precision, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
001-38677
38-3661826
(State or other jurisdiction of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
 
1670 Highway 160 West
Suite 205
Fort Mill, SC 29708
(Address of principal executive offices, including zip code)
 
(973) 691-2000
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report.)
-----------------------------
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
VTAK
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2):
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01 Regulation FD Disclosure.
 
The Catheter Precision, Inc. Investor Presentation dated March 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits
 
 
Exhibit
 
Description
99.1
  
104
  
Cover Page Interactive Data File (formatted as inline XBRL)
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
CATHETER PRECISION, INC.
Date: March 12, 2025
By:
/s/ Philip Anderson
Philip Anderson
  Chief Financial Officer  
 
 
 
Get the next $VTAK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VTAK

DatePrice TargetRatingAnalyst
More analyst ratings

$VTAK
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

    BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE:VTAK) ("Catheter Precision" or the "Company"), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts. By partnering with PCG Advisory, Catheter Precision seeks to strengthen its engagement with institutional and retail investors, effectively communicate its strategic vision, and increase market awareness of its LockeT and VIVO™ technologies—t

    $VTAK
    Medical/Dental Instruments
    Health Care

  • Catheter Precision, Inc. Announces The Closing of its Acquisition of PeriKard, LLC

    FORT MILL, S.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announces that it has closed the previously announced acquisition of PeriKard, LLC. David Jenkins, CEO of Catheter Precision, commented on the acquisition, "We are happy to have closed on this all-stock transaction within our anticipated timeline. The acquired technology will complement our emphasis on the ventricular therapeutic market and expectation for continuing growth in this market segment". About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solut

    $VTAK
    Medical/Dental Instruments
    Health Care

  • Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium

    FORT MILL, SOUTH CAROLINA / ACCESS Newswire / January 16, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 30th International Atrial Fibrillation Symposium in from January 16 - 18, 2025 in Boston, Massachusetts.The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 30 years, the meeting has become a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent inve

    $VTAK
    Medical/Dental Instruments
    Health Care

$VTAK
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VTAK
 SEC Filings

See more

$VTAK
 Leadership Updates

Live Leadership Updates

See more

  • Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    $VTAK
    Medical/Dental Instruments
    Health Care

  • Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    $VTAK
    Medical/Dental Instruments
    Health Care

$VTAK
 Financials

Live finance-specific insights

See more

  • Catheter Precision, Inc. Announces Third Quarter Update and Financial Results

    FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i

    $VTAK
    Medical/Dental Instruments
    Health Care

  • Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q

    FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023.Highlights of the third quarter include the following: Received approval for first purchase in France. VIVO is now active in six European countries. Completed enrollment of Phase I LockeT study in excess of 100 patients. Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT. Finalized n

    $VTAK
    Medical/Dental Instruments
    Health Care

  • CATHETER PRECISION, INC. Reports Filing of 10-Q and Second Quarter Results of Operations

    FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.Highlights of the second quarter include the following:US sales team was assembled, trained, and is creating a pipeline.Additional US clinical personnel were onboarded and trained.Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024.Key VIVO accounts continue to be established in both the US and Europe.Initiation of first L

    $VTAK
    Medical/Dental Instruments
    Health Care

$VTAK
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more